Novartis diabetes drug delayed
13th Nov 2006, 15:49 GMT
The Swiss pharmaceutical company, on Monday said it had delayed approval by US regulators of Galvus, its new potential blockbuster diabetes drug, by three months
Novartis diabetes drug delayed related news:
- U.S. delays Novartis diabetes drug — Marketplace by Bloomberg - International Herald Tribune
- Novartis diabetes drug faces three month delay — Pharmaceutical Business Review Latest News
- FDA Decision on Novartis Drug Is Delayed — WSJ.com: What's News Europe
- FDA Extends Novartis Drug Review — WSJ.com: What's News Europe
- FDA Review on Novartis Galvus Extended — Government/ Industry Regulation News from StratCenter.com
- Novartis Diebetes Drug Gets FDA Setback — StratWire - Business of Healthcare NewsFeed
- Delay for FDA approval of diabetes drug — WISTV - Health
- Diabetes drug may cut heart risks — MSNBC.com: Health
- Diabetes drug may reduce cardiovascular risks — EurekAlert! - Medicine and Health
- Diabetes drug stalls heart disease — United Press International - Health Business
Latest news from FT.com - Companies:
- Amec spurns private equity approach
- Deutsche Telekom turns to Obermann
- Resolution in talks over possible deal
- Ex-Chairman of insurer may bid for Tribune
- Nintendo plans to increase ad blitz for Wii
- Alstom cuts gearing as profits rise
- Arcelor Mittal's Dofasco sale blocked
- Majestic Wine serves up rise in profits
- Higher prices lift Wiseman
- Carr's profits hit by tough trading conditions